Antibody to capsular polysaccharide enhances the function of neutrophils from patients with AIDS against Cryptococcus neoformans

AIDS

Volumn 13, Issue 6, 1999, Pages 653-660

  Monari, Claudia ^a,b   Casadevall, Arturo ^a,b   Retini, Cinzia ^a,b   Baldelli, Franco ^a,b   Bistoni, Francesco ^a,b   Vecchiarelli, Anna ^a,b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

AIDS; Antibody; Cryptococcus neoformans; Fungi; Neutrophils

Indexed keywords

CD16 ANTIGEN; CD32 ANTIGEN; CD64 ANTIGEN; MONOCLONAL ANTIBODY; POLYSACCHARIDE; SUPEROXIDE; ZYMOSAN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANDIDA ALBICANS; CLINICAL ARTICLE; COLONY FORMING UNIT; CRYPTOCOCCUS NEOFORMANS; CYTOFLUOROMETRY; FUNGICIDAL ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUTROPHIL; PRIORITY JOURNAL;

ADULT; ANTIBODIES, MONOCLONAL; CANDIDA ALBICANS; COLONY COUNT, MICROBIAL; CRYPTOCOCCUS NEOFORMANS; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; NEUTROPHILS; PHAGOCYTOSIS; POLYSACCHARIDES; RECEPTORS, IGG; SUPEROXIDES;

EID: 0032992436     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199904160-00005     Document Type: Article

References (40)

1. Mitchell TC, Perfect JR: Cryptococcosis in the era of AIDS -100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995, 8:515-548.
2. Currie BP, Casadevall A: Estimation of the prevalence of cryptococcal infection among HIV infected individuals in New York City. Clin Infect Dis 1994, 19:1029-1033.
3. Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JJ: Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. Ann Intern Med 1986, 104:234-240.
4. Powderly VVC: Cryptococcal meningitis and AIDS. Clin Infect Dis 1993, 17:837-842.
5. Powderly VVG: Recent advances in the management of Cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996, 22(suppl2):S119-S123.
6. Spitzer ED, Spitzer SG, Freundlich LF, Casadevall A: Persistence of the initial infection in recurrent Cryptococcal meningitis. Lancet! 993, 341:595-596.
7. Devi SJN: Preclinical efficacy of a glucuronoxylomannantetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 1996, 14:841-842.
8. Casadevall A, Cleare W, Feldmesser M, et al.: Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother 1998, 42:1437-1446.
9. Dromer F, Charreire J: Improved amphotericin B activity by a monoclonal anti-Crypfococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. I Infect Dis 1991, 163:1114-1120.
10. Cordon MA, Lapa E: Serum protein enhancement of antibiotic therapy in cryptococcosis. J Infect Dis 1964,114:373-378.
11. Mukherjee J, Feldmesser M, Scharff MD, Casadevall A: Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole activity. Antimicrob Agents Chemother 1995, 39:1398-1405.
12. Mukherjee J, Zuckier L, Scharff MD, Casadevall A: Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with Amphotericin B. Antimicrob Agents Chemother 1994, 38:580-587.
13. Deshaw M, Pirofski L: Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV positive and HIV negative individuals, j Clin fxp Immunol 1995, 99:425-432.
14. Diamond RD, Bennett JE: Prognostic factors in cryptococcal meningitis. Ann Intern Med 1974, 80:176-181.
15. Zhang H, Zhong Z, Pirofski L: Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody. Infect Immun 1997,65:1158-1164.
16. Macher AM, Bennett JE, Cadek JE, Frank MM: Complement depletion in cryptococcal sepsis. 1 Immunol 1978, 120:1686-1690.
17. Yuan R, Casadevall A, Oh J, Scharff MD: T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc Natl Acad Sei USA 1997, 94:2483-2488.
18. Cassone A, Palma C, Djeu JY, Aiuti F, Quinti I: Anticandidal activity and inlerleukin-1 and interleukin-6 production by polymorphonuclear leukocytes are preserved in subjects with AIDS.yO/n Microbiol 1993, 31:1354-1357.
19. Tascini C, Baldelli F, Monari C, et al.: Inhibition of fungicidal activity of polymorphonuclear leukocytes from HIV-infected patients by interleukin (IL)-4 and IL-10. AIDS 1996, 10:477-483.
20. Vecchiarelli A, Monari C, Baldelli F, et ai: Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS. I Infect Dis 1995, 171:1448-1454.
21. Roilides E, Holmes A, Blake C, Pizzo PA, VValsh TJ: Impairment of neutrophil antifungal activity against hyphae of Aspergillus fumlgalus in children infected with human immunodeficiency virus. ; Infect Dis 1993, 167:905-911.
22. Roilides E, Merlins S, Eddy S, Walsh TJ, Pizzo PA, Rubin M: Impairment of neutrophil chemotactic and bactericidal function in HIV-infected children and partial reversal after in vitro exposure to granulocyte-macrophago colony-stimulating factor. I Pediatr 1990, 117:531-540.
23. Ashman RB, Papadimitriou JM: Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiol Rev 1995, 59:646-672.
24. Sawyer DVV, Donowitz CR, Mandell CL: Polymorphonuclear neutrophils: an effective antimicrobial force. Rev Infect Dis 1989, 11:51532-51542.
25. Lovchik JA, Lipscomb MF: Role for C5 and neutrophils in the pulmonary intravascular clearance of circulating Cryptococcus neoformans. Am 1 Respir Cell Mol Biol 1993, 9:617-627.
26. Craybill JR, Mitchell L: Cyclophosphamide effects on murine cryptococcosis. Infect Immun 1978, 21:674-677.
27. Craybill JR, Bocanegra R, Lambros C, Luther MF: Granulocyte colony stimulating factor therapy of experimental cryptococcal meningitis. ; Med Vet Mycol 1997, 35:243-247.
28. Diamond RD, Root RK, Bennett JE: Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro. ] Infect Dis 1972, 125:367-376.
29. Tacker JB, Farh F, Bulmer CS: Intracellular fate of Cryptococcus neoformans. Infect Immun 1972, 6:162-167.
30. Zhong Z, Pirofski L: Antifungal activity of a human antiglucuronoxylomannan antibody. Clin Diagn Lab Immunol 1998, 5:58-64.
31. Mukerjee J, Casadevall A, Scharff MD: Molecular characterization of the antibody responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus-toxoid conjugale immunization. J Exp Med 1993, 177:1105-1106
32. Chaisson RE, Volberding PA: Clinical manifestations of HIV infection. In Principles and Practice of Infectious Diseases. Edited by Mandell CL, Bennett JE, Dolin R. New York: Churchill Livingstone; 1995:1217-1253.
33. Mohsenin V, Latifpour J: Respiratory burst in alveolar macrophages of diabetic rats. ] Appl Physiol 1990, 68:2384-2390.
34. Kozel TR, dejong BCH, Grinsell MM, MacGill RS, Wall KK: Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule. Infect Immun 1998, 66:1538-1546.
35. Vecchiarelli A, Retini C, Casadevall A, Monari C, Pietrella D, Kozel TR: Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular polysaccharide material of Cryptococcus neoformans. Infect Immun 1998, 66:4324-4330.
36. Brummer E, Stevens DA: Macrophage colony-stimulating factor induction of enhanced macrophage anticryptococcal activity: synergy with fluconazole for killing. I Infect Dis 1994, 170:173-179.
37. Brummer E, Nassar F, Stevens DA: Effect of macrophage colony-stimulating factor on anticryptococcal activity of bronchoalveolar macrophages: synergy with fluconazole for killing. Antimicrob Agents Chemother 1994, 38:2158-2161.
38. Chang YC, Kwon-Chung KJ: Complementation of a capsuledeficient mutation of Cryptococcus ncoformans restores its virulence. Mol Cell Biol 1994, 14:4912-4919.
39. Casadevall A, Perfect JR: Cryptococcus neoformans. Washington: ASM Press; 1998.
40. Macintyre EA, Roberts PJ, Jones M, et al.: Activation of human monocytes occurs on cross-linking monocytic antigens to an Fc receptor. 1 Immunol 1989, 142:2377-2383.